Previous 10 | Next 10 |
2023-11-08 17:22:15 ET Amphastar Pharmaceuticals press release ( NASDAQ: AMPH ): Q3 Non-GAAP EPS of $1.15 beats by $0.46 . Revenue of $180.6M (+50.3% Y/Y) beats by $6.8M . For further details see: Amphastar Pharmaceuticals Non-GAAP EPS of $1.15 beats by $...
Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2023. Th...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Amphastar Pharmaceuticals Inc. (AMPH) is expected to report $0.67 for Q3 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to ...
2023-10-10 21:41:26 ET Summary Amphastar Pharmaceuticals has implemented aggressive corporate strategies to maximize margins and increase sales, resulting in impressive EBIT and revenue growth. The company's focus on high-margin products and strategic acquisitions has contributed ...
2023-09-26 07:00:00 ET Summary Amphastar's Q2 2023 financials show an 18% YoY revenue growth and 50% net income increase, outpacing sector performance. Strategic $300M convertible senior notes offering aims to restructure debt and enable stock repurchases, potentially improving li...
2023-09-13 05:10:45 ET More on Amphastar Pharmaceuticals Financial information for Amphastar Pharmaceuticals Amphastar's Generic Drug Rush Gains Momentum Amphastar Pharma: A Company Growing Quickly As Acquisitions Likely Fuel Growth For further details see: ...
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably beli...
2023-09-11 16:58:16 ET More on Amphastar Pharmaceuticals Seeking Alpha’s Quant Rating on Amphastar Pharmaceuticals Historical earnings data for Amphastar Pharmaceuticals Financial information for Amphastar Pharmaceuticals Amphastar's Generic Drug Rush ...
News, Short Squeeze, Breakout and More Instantly...
Amphastar Pharmaceuticals Inc. Company Name:
AMPH Stock Symbol:
NASDAQ Market:
Amphastar Pharmaceuticals Inc. Website:
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, M...
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024. First Quarter ...